Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient Perspectives
- PMID: 33291156
- DOI: 10.1055/a-1298-4546
Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient Perspectives
Abstract
Introduction: There are many possible treatment goals for patients with schizophrenia. Two major perspectives on treatment goals are the patient's and the physician's perspective. Patient-centered treatment mandates that an individual patient's treatment goals are taken into account when treatment is planned. In this narrative review, we address the commonalities and differences of the patient's and physician's perspectives.
Methods: We searched for literature on treatment goals for patients with schizophrenia from the last 10 years.
Results: Fifty-two relevant records were identified, 4 of which directly compare patient's and physician's perspectives. Two further articles used the same set of goals to ask patients or physicians for their assessment.
Discussion: Agreement between patients and physicians regarding valuation of treatment goals was high. However, physicians tended to put more emphasis on the classical "textbook" goals of symptom resolution and functioning, while patients stressed well-being and quality of life more. Results on treatment goals from patients are difficult to generalize, since recruiting representative patient samples is challenging and patient subgroups may have differing priorities.
Thieme. All rights reserved.
Conflict of interest statement
Dr. Gründer has served as a consultant for Allergan, Boehringer Ingelheim, Institute for Quality and Efficiency in Health Care (IQWiG), Janssen-Cilag, Lundbeck, Otsuka, Recordati, Sage, and Takeda. He has served on the speakers’ bureau of Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Recordati. He has received grant support from Boehringer Ingelheim, Lundbeck, and Saladax. He is co-founder and/or shareholder of Mind and Brain Institute GmbH, Brainfoods GmbH, InMediCon GmbH, OVID Health Systems GmbH and MIND Foundation gGmbH. Dr. Bauknecht is an employee of Dr. Carl GmbH. Dr. Klingberg declares no conflicts of interest. Dr. Leopold received speaker’s fees and travel reimbursements from Janssen-Cilag, Lilly, Lundbeck, Otsuka, and Recordati. She has received grant support from Otsuka and Janssen-Cilag. Dr. Paulzen received speaker’s fees from Lundbeck and Neuraxpharm. Dr. Schell received speaker’s fees and travel reimbursements from Janssen-Cilag, Lundbeck, and Otsuka. Dr. Stengler declares no conflicts of interest. Dr. Leucht has received honoraria for service as a consultant or adviser and/or for lectures from Angelini, Boehringer Ingelheim, Gedeon Richter, Janssen, Johnson & Johnson, LB Pharma, LTS Lohmann, Lundbeck, MSD, Otsuka, Recordati, Sandoz, Sanofi-Aventis, Sunovion, and TEVA.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
